Abstract library

372 results for "systemic chemotherapy".
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System
Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: MD Tomohiro Yamaguchi
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Lee K, Kim K P, Chang H M, ...
#557 The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)
Introduction: GEPNETs represent a heterogenous family of tumors of challenging clinical management. Treatment of advanced disease is evolving, including some recent relevant achievements with novel targeted agents. How to best integrate these new agents with conventional chemotherapy(CT) is still a matter of debate.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Rocio Garcia-Carbonero
Keywords: chemotherapy
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)
Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Philippa Davies
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...